Coloplast Valuation
Is 020259063 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 020259063 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 020259063 (CHF109.67) is trading above our estimate of fair value (CHF90.24)
Significantly Below Fair Value: 020259063 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 020259063?
Key metric: As 020259063 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 020259063's PE Ratio? | |
|---|---|
| PE Ratio | 39.4x |
| Earnings | DKK 4.71b |
| Market Cap | DKK 185.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9x |
| Enterprise Value/EBITDA | 27x |
| PEG Ratio | 3.9x |
Price to Earnings Ratio vs Peers
How does 020259063's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.9x | ||
ALC Alcon | 36x | 9.4% | CHF 37.2b |
YPSN Ypsomed Holding | 66.8x | 40.6% | CHF 5.0b |
SOON Sonova Holding | 31.3x | 8.7% | CHF 18.8b |
STMN Straumann Holding | 61.4x | 20.9% | CHF 17.7b |
020259063 Coloplast | 39.4x | 10.2% | CHF 185.4b |
Price-To-Earnings vs Peers: 020259063 is good value based on its Price-To-Earnings Ratio (39.4x) compared to the peer average (47.9x).
Price to Earnings Ratio vs Industry
How does 020259063's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 020259063 is expensive based on its Price-To-Earnings Ratio (39.4x) compared to the European Medical Equipment industry average (31.3x).
Price to Earnings Ratio vs Fair Ratio
What is 020259063's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 020259063's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Becton Dickinson
US$66.7b
Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
912061
US$238.02
7D
0%
1Y
-2.2%
Galenica
CHF 3.7b
Operates as a healthcare service provider in Switzerland and internationally.
GALE
CHF 75.00
7D
-1.6%
1Y
6.5%
Fresenius Medical Care
€9.9b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
FME
€81.20
7D
0%
1Y
0%